Delisting risk
Acurx Pharmaceuticals (ACXP)
Developing selective-spectrum antibiotics for C. difficile and other Gram-positive infections.
$1.42
Pre-market−0.02 (−1.05%)
At close$1.44(+2.50%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions22 holders · as of Mar 31, 2026 | 3.48% | 183.2K shares | |
| Insiders6 holders · as of Jan 8, 2025 | 2.20% | 115.8K shares | |
| Otherremainder | 94.32% | 4.97M shares |
5.27M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (5.27M in the company's Sep 3, 2026 report, 4.30M elsewhere); stakes use the report.
Institutions13F, as of Mar 31, 2026
22 holders · 183.2K shares · 8 new positions · 11 increased · 4 reduced · 4 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Jane Street Group, LLC | 54.6K | 1.04% | +43.9K | May 12, 2026 |
| Vanguard Capital Management LLC | 31.1K | 0.59% | +31.1Knew | May 15, 2026 |
| Geode Capital Management, LLC | 24.8K | 0.47% | +12.4K | May 15, 2026 |
| Cambridge Investment Research Advisors, Inc. | 20.0K | 0.38% | +20.0Knew | Apr 30, 2026 |
| Vanguard Fiduciary Trust Co | 16.2K | 0.31% | +16.2Knew | May 8, 2026 |
| Prospect Financial Services LLC | 13.8K | 0.26% | −6.0K | Apr 24, 2026 |
| Morgan Stanley | 6.5K | 0.12% | 0 | May 15, 2026 |
| UBS Group AG | 6.3K | 0.12% | +6.1K | May 5, 2026 |
Ownership statements13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Insider tradesForm 4
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.